Type 1 Diabetes trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Type 1 Diabetes. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month13 studies across 6 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | Teplizumab in Pediatric Stage 2 Type 1 DiabetesNCT05757713Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), TEAEs leading to withdrawal, and serious adverse events (SAEs) | Phase 4 | Active, not recruiting | 2026-08-27 | in 7 d | 2026-01-30 |
September 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 DiabetesNCT07087795Part A: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL) | Phase 1 | Active, not recruiting | 2026-09-12 | in 23 d | 2026-08-13 |
| VRTX | Vertex Pharmaceuticals Incorporated | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantNCT06832410Proportion of Participants who are Insulin Independent | Phase 3 | Recruiting | 2026-09-17 | in 28 d | 2026-03-23 |
| LLY | Eli Lilly and Company | A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)NCT06280703Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration. | Phase 1 | Recruiting | Sep 2026 | ≤ 41 d | 2026-01-20 |
November 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightNCT06914895Change from Baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-05-12 |
| LLY | Eli Lilly and Company | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightNCT06962280Change from Baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-02-17 |
| SNY | Sanofi | Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)NCT07457580observationalParticipant demographics at teplizumab initiation | — | Recruiting | 2026-11-30 | in 102 d | 2026-05-27 |
December 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)NCT07038473Proportion of at-risk (first-degree) relatives of T1D probands who meet the diagnostic criteria for Stage 1 or Stage 2 T1D | Not applicable | Recruiting | 2026-12-25 | in 127 d | 2026-08-19 |
| LLY | Eli Lilly and Company | A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesNCT06945406Number of Participants with One or More Serious Adverse Event(s) (SAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-03-11 |
| PODD | Insulet Corporation | Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1DNCT07593625Percentage of time <54 mg/dL | Not applicable | Recruiting | 2026-12-31 | in 133 d | 2026-07-20 |
January 2027 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood SugarNCT07160816observationalChange in glycated haemoglobin (HbA1c) | — | Active, not recruiting | 2027-01-20 | in 153 d | 2026-06-29 |
| NVO | Novo Nordisk A/S | A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesNCT07076199Change in glycosylated haemoglobin (HbA1c) | Phase 3 | Recruiting | 2027-01-25 | in 158 d | 2026-06-29 |
| CELZ | Creative Medical Technology Holdings Inc | Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 DiabetesNCT05626712Number of Participants with Adverse Events | Phase 1/2 | Recruiting | 2027-01-31 | in 164 d | 2026-02-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Type 1 Diabetes
most recently updated first499 studies match. Showing the first 100 of 499 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNY | Sanofi | — | Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)NCT07038473Proportion of at-risk (first-degree) relatives of T1D probands who meet the diagnostic criteria for Stage 1 or Stage 2 T1D | Not applicable | Recruiting | Procedure: Investigational Procedure | Type 1 Diabetes | 3,500 | 2025-12-17 | 2026-12-25 | in 127 d | 2026-08-19 |
| NVO | Novo Nordisk A/S | — | A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 DiabetesNCT07087795Part A: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL) | Phase 1 | Active, not recruiting | Drug: NNC0194-0499, Placebo, Semaglutide | Diabetes Mellitus, Type 1 | 96 | 2025-07-01 | 2026-09-12 | in 23 d | 2026-08-13 |
| MNKD | Mannkind Corporation | $1.3B | INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesNCT07224321Percentage of participants with Continuous Glucose Meter (CGM) measured time in range (TIR) ≥70% | Phase 2 | Recruiting | Drug: Technosphere Insulin, Technosphere Insulin, Basal insulin | Type 1 Diabetes Mellitus | 100 | 2026-02-04 | Mar 2027 | ≤ 223 d | 2026-08-13 |
| SNY | Sanofi | — | A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesNCT07088068For United States (US) and non-European Union (EU) countries: Glycated hemoglobin (HbA1c) change from baseline | Phase 3 | Recruiting | Drug: Teplizumab · Other: Placebo | Type 1 Diabetes Mellitus | 723 | 2025-08-06 | 2028-06-06 | in 656 d | 2026-08-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and AdultsNCT07222137Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes | Phase 3 | Recruiting | Drug: Baricitinib, Placebo | Diabetes Mellitus, Type 1 | 150 | 2026-01-12 | Jul 2031 | ≤ 1,806 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)NCT07222332Change from Baseline in C-peptide Area Under the Curve (AUC) | Phase 3 | Recruiting | Drug: Baricitinib, Placebo | Diabetes Mellitus, Type 1 | 300 | 2026-02-05 | Jul 2028 | ≤ 711 d | 2026-08-06 |
| PODD | Insulet Corporation | $10.3B | French Prospective Multicentric Study in Real WorldNCT07039942observationalChange in the percentage of time in the 70 - 180 mg/dL range (TIR) | — | Active, not recruiting | Device: Omnipod 5 | Diabetes, Diabetes Mellitus, Type 1 Diabetes | 304 | 2025-07-23 | 2027-07-30 | in 344 d | 2026-08-03 |
| PODD | Insulet Corporation | $10.3B | Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)NCT07317102observationalChange in the percentage of time in the 70 - 180 mg/dL range | — | Recruiting | Device: Omnipod 5 | Diabetes, Type 1 Diabetes, Diabetes Mellitus | 152 | 2026-03-16 | Nov 2027 | ≤ 467 d | 2026-08-03 |
| PODD | Insulet Corporation | $10.3B | Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 SystemNCT07579702Time in Range 70-180 mg/dL | Not applicable | Recruiting | Device: Omnipod 5 System, Omnipod 6 System | Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus | 200 | 2026-05-13 | 2027-02-22 | in 186 d | 2026-08-03 |
| VTVT | vTv Therapeutics | — | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesNCT06334133Change in incidence of Level 2 or Level 3 hypoglycemia | Phase 3 | Active, not recruiting | Drug: Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo | Diabetes Mellitus, Type 1 | 150 | 2024-06-14 | Apr 2027 | ≤ 253 d | 2026-07-28 |
| PODD | Insulet Corporation | $10.3B | Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1DNCT07593625Percentage of time <54 mg/dL | Not applicable | Recruiting | Device: Omnipod M System, Omnipod S | Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetes (DM) | 80 | 2026-05-25 | 2026-12-31 | in 133 d | 2026-07-20 |
| SABS | SAb Biotherapeutics, Inc. | $345M | SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 DiabetesNCT07187531Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) | Phase 2 | Recruiting | Drug: High Dose SAB-142, Low Dose SAB-142 · Other: Placebo | Type 1 Diabetes | 159 | 2025-11-25 | Nov 2027 | ≤ 467 d | 2026-07-10 |
| PODD | Insulet Corporation | $10.3B | Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 DiabetesNCT06144554observationalIncidence rate of severe hypoglycemia | — | Recruiting | Device: Omnipod 5 | Type 1 Diabetes | 2,200 | 2023-09-25 | Jun 2027 | ≤ 314 d | 2026-07-01 |
| SNY | Sanofi | — | Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 DiabetesNCT06791291Number of participants with Stage 3 Type 1 Diabetes based on American Diabetes Association criteria | Phase 2 | Recruiting | Drug: Teplizumab | Type 1 Diabetes Mellitus | 10 | 2025-07-25 | 2028-03-06 | in 564 d | 2026-07-01 |
| VRTX | Vertex Pharmaceuticals Incorporated | $133.9B | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 DiabetesNCT04786262Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) | Phase 3 | Recruiting | Biological: VX-880 | Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia | 52 | 2021-03-29 | 2027-06-30 | in 314 d | 2026-06-30 |
| SNY | Sanofi | — | Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)NCT06111586Change in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC from baseline to W52 for Part B (12-21 y.o.) | Phase 2 | Active, not recruiting | Drug: Frexalimab, Placebo, Insulin | Type 1 Diabetes Mellitus | 197 | 2023-12-11 | 2027-04-28 | in 251 d | 2026-06-29 |
| NVO | Novo Nordisk A/S | — | General Use-results Surveillance With Awiqli in Patients With Diabetes MellitusNCT06807190observationalNumber of Adverse Reactions (ARs) | — | Recruiting | Drug: Insulin Icodec | Diabetes Mellitus, Type 1 | 630 | 2025-04-15 | 2027-07-31 | in 345 d | 2026-06-29 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesNCT07076199Change in glycosylated haemoglobin (HbA1c) | Phase 3 | Recruiting | Drug: Insulin icodec, Insulin glargine, Insulin aspart | Diabetes Mellitus, Type 1 | 877 | 2025-08-11 | 2027-01-25 | in 158 d | 2026-06-29 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood SugarNCT07160816observationalChange in glycated haemoglobin (HbA1c) | — | Active, not recruiting | Drug: Insulin icodec | Diabetes Mellitus, Type 1 | 245 | 2025-08-28 | 2027-01-20 | in 153 d | 2026-06-29 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | Control-IQ Technology 2.0 Adult and Adolescent Feasibility StudyNCT05014789results2026-06-01Overall Percent Time Less Than 54 mg/dL | Not applicable | Completed | Device: Control-IQ technology 2.0 | Diabetes Mellitus, Type 1 | 66 | 2021-08-19 | 2021-12-20actual | — | 2026-06-24 |
| NVO | Novo Nordisk A/S | — | A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 DiabetesNCT07305805AUC, GIR,SS: Area under the glucose infusion rate-time curve at steady state | Phase 1 | Completed | Drug: NNC0363-1063 | Diabetes Mellitus, Type 1 | 36 | 2025-12-16 | 2026-04-21actual | — | 2026-06-05 |
| VRTX | Vertex Pharmaceuticals Incorporated | $133.9B | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 DiabetesNCT05791201Part A and Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1/2 | Active, not recruiting | Drug: VX-264 | Type 1 Diabetes | 7 | 2023-05-16 | 2027-03-12 | in 204 d | 2026-06-04 |
| NVO | Novo Nordisk A/S | — | A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or ObesityNCT07578584Number of adverse events | Phase 1 | Recruiting | Drug: NNC0497-0040, Placebo | Type 1 Diabetes (T1D), Overweight, Obesity, Healthy Volunteers | 146 | 2026-05-07 | 2028-02-18 | in 547 d | 2026-06-04 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 DiabetesNCT073254617 Day Survival of Infusion Set for Primary Outcome Measure | Not applicable | Active, not recruiting | Device: SteadiSet Infusion Set | Diabetes Mellitus, Type 1 | 20 | 2026-02-18 | 2027-03-01 | in 193 d | 2026-06-01 |
| VTVT | vTv Therapeutics | — | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) SystemsNCT07616206To assess the change in Time in Range (TIR) | Phase 2 | Not yet recruiting | Drug: Cadisegliatin 800 mg QD, Placebo | Type 1 Diabetes (T1D) | 40 | Jul 2026 | Apr 2027 | ≤ 253 d | 2026-06-01 |
| SNY | Sanofi | — | Long-Term Outcomes of Teplizumab in Routine Clinical CareNCT07360080observationalTime from teplizumab infusion start to the onset of Stage 3 T1D | — | Recruiting | Drug: Teplizumab | Type 1 Diabetes | 1,000 | 2026-03-19 | 2035-10-29 | in 3,357 d | 2026-05-27 |
| SNY | Sanofi | — | Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)NCT07457580observationalParticipant demographics at teplizumab initiation | — | Recruiting | Drug: Teplizumab | Type 1 Diabetes | 60 | 2026-03-16 | 2026-11-30 | in 102 d | 2026-05-27 |
| BMEA | Biomea Fusion Inc. | $98M | Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes MellitusNCT06152042To assess the effect on endogenous insulin secretion | Phase 2 | Terminatedsponsor's stated reason: Sponsor made a business decision to terminate the study based on prioritization of portfolio. | Drug: BMF-219 | Type 1 Diabetes Mellitus | 37 | 2023-12-28 | 2025-05-20actual | — | 2026-05-14 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightNCT06914895Change from Baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Active, not recruiting | Drug: Tirzepatide, Placebo | Type 1 Diabetes, Obesity, Overweight | 905 | 2025-04-25 | Nov 2026 | ≤ 102 d | 2026-05-12 |
| CRSP | CRISPR Therapeutics AG | $5.1B | An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1DNCT05565248Incidence of adverse events with causality related to VCTX211 units, the surgical procedures and/or medical interventions required to implant and explant the VCTX211 units. | Phase 1 | Terminatedsponsor's stated reason: Patients to be followed up in the VCTX-201 study | Combination product: VCTX211 | Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases | 5 | 2023-01-20 | 2025-08-08actual | — | 2026-05-07 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | Tandem Freedom - Feasibility Trial 2NCT06834568results2026-02-06Number of Participants With One or More Severe Hypoglycemia Events | Not applicable | Completed | Device: t:slim X2 insulin pump with Tandem Freedom Algorithm | Diabetes Mellitus, Type 1 | 10 | 2025-03-24 | 2025-04-07actual | — | 2026-05-05 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in FranceNCT07211126observationalRate of diabetic ketoacidosis (DKA). | — | Recruiting | Device: t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) | Diabetes Mellitus, Type 1 | 350 | 2026-03-03 | Dec 2027 | ≤ 498 d | 2026-05-01 |
| SENS | Senseonics, Inc. | $459M | Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement FeatureNCT07386340System agreement (15/15%, 20/20%, 30/30%, and 40/40%) for paired sensor FGM and reference measurements post-insertion for reference glucose values from 40-400 mg/dL. | Not applicable | Recruiting | Device: Continuous Glucose Monitoring System | Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 80 | 2025-12-29 | Dec 2027 | ≤ 498 d | 2026-04-21 |
| PODD | Insulet Corporation | $10.3B | Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and AdultsNCT05923827results2026-04-14Change in HbA1c (%) | Not applicable | Completed | Device: Omnipod 5 System | Diabetes Mellitus, Type 1 | 189 | 2023-09-11 | 2024-08-16actual | — | 2026-04-14 |
| SNY | Sanofi | — | Registry for Stage 2 Type 1 DiabetesNCT06481904observationalNumber of adverse events of special interests (AESI) | — | Recruiting | Drug: TZIELD (teplizumab-mzwv) | Type 1 Diabetes | 200 | 2024-09-27 | 2037-01-15 | in 3,801 d | 2026-04-13 |
| NVO | Novo Nordisk A/S | — | An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical PracticeNCT03987802observationalAdverse Events (AEs) | — | Completed | Drug: Faster-acting insulin aspart | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 42 | 2021-01-20 | 2022-06-28actual | — | 2026-04-09 |
| NVO | Novo Nordisk A/S | — | A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 DiabetesNCT06685185Part 1 SAD: Number of adverse events | Phase 1 | Completed | Drug: NNC0363-1063, Placebo, Insulin degludec, Insulin detemir | Diabetes Mellitus, Type 1 | 117 | 2024-11-12 | 2026-03-08actual | — | 2026-04-09 |
| NVO | Novo Nordisk A/S | — | User Experience With DuraTouch® in Patients With Type 1 or Type 2 DiabetesNCT07052292observationalParticipant rating the ease of use, convenience and satisfaction with the device | — | Completed | Device: DuraTouch® | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 128 | 2025-07-01 | 2026-01-09actual | — | 2026-04-09 |
| IMCR | Immunocore Ltd | $1.9B | Study of IMC-S118AI in Type 1 DiabetesNCT07493122Number of participants with ≥1 treatment-emergent serious adverse event (SAE) | Phase 1 | Not yet recruiting | Biological: IMC-S118AI | Type 1 Diabetes, Type 1 Diabetes (T1D), Diabetes Type 1 | 154 | Apr 2026 | Nov 2030 | ≤ 1,563 d | 2026-03-25 |
| VRTX | Vertex Pharmaceuticals Incorporated | $133.9B | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantNCT06832410Proportion of Participants who are Insulin Independent | Phase 3 | Recruiting | Biological: Biological/Vaccine | Type 1 Diabetes, Kidney Transplant | 10 | 2025-03-31 | 2026-09-17 | in 28 d | 2026-03-23 |
| PROK | Prokidney | $85M | Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)NCT05018416Improvement in renal function progression rate as indicated by the change from pre-injection baseline value in total (acute + chronic) slope of estimated glomerular filtration rate (eGFR) using the CKD-EPI 2009 equation | Phase 2 | Completed | Biological: Renal Autologous Cell Therapy (REACT) | Chronic Kidney Diseases, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 53 | 2021-07-27 | 2025-05-20actual | — | 2026-03-13 |
| SNY | Sanofi | — | Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® MoleculeNCT06812988Change from baseline to Week 26 in mean 2-hour mixed meal tolerance test (MMTT) stimulated C-peptide concentration | Phase 2 | Active, not recruiting | Drug: Brivekimig, Placebo | Type 1 Diabetes Mellitus | 84 | 2025-02-28 | 2027-04-29 | in 252 d | 2026-03-13 |
| MESO | Mesoblast, Inc. | — | PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)NCT00690066C-peptide area under the concentration curve (AUC) response (MMTT) | Phase 2 | Completed | Drug: PROCHYMAL®, Placebo | Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes | 63 | 2008-06-11 | 2010-12-12actual | — | 2026-03-11 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesNCT06945406Number of Participants with One or More Serious Adverse Event(s) (SAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Recruiting | Drug: LY4057996 SC, LY4057996 IV, Placebo SC, Placebo IV, Degludec SC, Lispro SC, Degludec IV, Pre-study basal insulin SC | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 124 | 2025-05-16 | Dec 2026 | ≤ 133 d | 2026-03-11 |
| CELZ | Creative Medical Technology Holdings Inc | $7M | Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 DiabetesNCT05626712Number of Participants with Adverse Events | Phase 1/2 | Recruiting | Biological: CELZ-201 Administration · Other: Control Group | Type 1 Diabetes, Diabetes Mellitus, Type 1 | 18 | 2023-04-07 | 2027-01-31 | in 164 d | 2026-02-19 |
| LLY | Eli Lilly and Company | $1.15T | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightNCT06962280Change from Baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Active, not recruiting | Drug: Tirzepatide, Placebo | Type 1 Diabetes, Obesity, Overweight | 465 | 2025-05-12 | Nov 2026 | ≤ 102 d | 2026-02-17 |
| SNY | Sanofi | — | Teplizumab in Pediatric Stage 2 Type 1 DiabetesNCT05757713Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), TEAEs leading to withdrawal, and serious adverse events (SAEs) | Phase 4 | Active, not recruiting | Biological: teplizumab | Diabetes Mellitus, Type 1 | 20 | 2023-07-25 | 2026-08-27 | in 7 d | 2026-01-30 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)NCT06280703Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration. | Phase 1 | Recruiting | Drug: LY3938577, Placebo, Insulin Degludec, Insulin Lispro, LY3938577, Placebo, Insulin Degludec, Basal Insulin, Lispro Prandial Insulin | Healthy, Type 1 Diabetes Mellitus | 118 | 2024-05-15 | Sep 2026 | ≤ 41 d | 2026-01-20 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical PracticeNCT05069545observationalChange in time in range (3.9-10 mmol/L) | — | Completed | Drug: Insulin degludec, Fast-acting insulin aspart | Diabetes Mellitus, Type 1 | 411 | 2021-10-11 | 2024-09-10actual | — | 2025-12-31 |
| NVO | Novo Nordisk A/S | — | Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese AdolescentsNCT06588504Adults cohort: Time to plasma glucose (PG) recovery, where PG recovery is defined as the first increase in PG of greater than or equal to (>=) 20 milligrams per decilitre (mg/dL) (1.1 millimoles per litre [mmol/L]) from baseline | Phase 1 | Completed | Drug: Dasiglucagon, Glucagon | Diabetes Mellitus, Type 1 | 38 | 2024-09-10 | 2025-07-20actual | — | 2025-12-05 |
| NVO | Novo Nordisk A/S | — | Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With DiabetesNCT04588259results2024-03-20Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage [%]) | Phase 3 | Completed | Drug: Faster aspart, Insulin aspart, Insulin degludec | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 331 | 2020-10-09 | 2022-07-05actual | — | 2025-12-04 |
| NVO | Novo Nordisk A/S | — | A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 DiabetesNCT04698018AUCIAsp,0-30min, area under the serum insulin aspart concentration-time curve from 0 to 30 minutes | Phase 1 | Completed | Drug: Faster Aspart, Novo Rapid | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 23 | 2021-04-20 | 2022-07-20actual | — | 2025-12-04 |
| NVO | Novo Nordisk A/S | — | A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)NCT04848480results2025-06-12Change in Glycosylated Haemoglobin (HbA1c) at Week 26 | Phase 3 | Completed | Drug: insulin icodec, insulin degludec, insulin aspart | Diabetes Mellitus, Type 1 | 582 | 2021-04-30 | 2022-04-28actual | — | 2025-12-04 |
| SNY | Sanofi | — | A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United StatesNCT07260110observationalChange in participant and caregiver-reported outcomes from survey responses: ease of diabetes management questions | — | Recruiting | Drug: Teplizumab | Type 1 Diabetes | 550 | 2025-10-31 | 2030-12-03 | in 1,566 d | 2025-12-03 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | Tandem Freedom Feasibility Study 1NCT06428591results2025-11-18Severe Hypoglycemia Events | Not applicable | Completed | Device: t:slim X2 insulin pump with Tandem Freedom Algorithm | Diabetes Mellitus, Type 1 | 10 | 2024-05-29 | 2024-06-10actual | — | 2025-11-18 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | PS230005 Control-IQ 1.5 Post-Approval StudyNCT06717451observationalIncidence Rates of Severe Hypoglycemia (SH) | — | Active, not recruiting | Device: Control-IQ Technology v1.5 | Type 1 Diabetes | 144 | 2025-01-30 | 2026-08-11 | — | 2025-11-12 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY8888AX in Participants Using a Connected Insulin Management PlatformNCT05893797results2025-11-10Number of Missed Bolus Doses (MBDs) Per Week | Not applicable | Completed | Drug: Insulin Lispro · Device: Tempo Smart Button, Dexcom G6 CGM, Glooko Research Mobile App (RMA) | Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin | 36 | 2023-10-05 | 2024-09-16actual | — | 2025-11-10 |
| SNY | Sanofi | — | A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 DiabetesNCT03903016Assessment of pharmacokinetc (PK) parameter:INS-Cmax | Phase 1 | Completed | Drug: Insulin Lispro SAR342434, Insulin Lispro SAR342434 | Type 1 Diabetes | 90 | 2019-03-26 | 2019-08-19actual | — | 2025-09-24 |
| PODD | Insulet Corporation | $10.3B | Omnipod 5 System Compared to Pump TherapyNCT05409131results2025-02-26Percent of Time in Range 70-180 mg/dL | Not applicable | Completed | Device: Omnipod 5 System | Type 1 Diabetes | 196 | 2022-07-07 | 2023-09-14actual | — | 2025-09-16 |
| NVO | Novo Nordisk A/S | — | A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin PumpNCT06809621AUC(GIR,0-1h,basal-corrected): Area under the basal-corrected glucose infusion rate (GIR)-time curve from 0 to 1 hour | Phase 1 | Completed | Drug: NNC0471-0119 H, Insulin aspart | Diabetes Mellitus, Type 1 | 43 | 2025-01-29 | 2025-07-16actual | — | 2025-09-02 |
| SNY | Sanofi | — | Description of Patients With Type 1 Diabetes Treated With TeplizumabNCT06892002observationalParticipant demographic characteristics at teplizumab initiation | — | Completed | Drug: Teplizumab | Type 1 Diabetes | 110 | 2025-02-11 | 2025-08-05actual | — | 2025-08-15 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study of a High-Dose Aflibercept in Participants With Diabetic Eye DiseaseNCT04429503results2023-11-21Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48 | Phase 2/3 | Completed | Drug: aflibercept, High-dose aflibercept | Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 660 | 2020-06-29 | 2022-05-30actual | — | 2025-08-08 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection TherapyNCT05463744results2025-06-24Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 [Noninferiority Analysis] | Phase 3 | Completed | Drug: Insulin Efsitora Alfa, Insulin Degludec | Type 1 Diabetes, Diabetes | 692 | 2022-08-12 | 2024-05-07actual | — | 2025-06-24 |
| SENS | Senseonics, Inc. | $459M | Post Approval Study of the Eversense® Continuous Glucose MonitoringNCT03908125results2025-06-12The Long-term Safety of the Eversense CGM Systems Over Repeat Insertion and Removal Cycles in the Post-market Setting. | Not applicable | Completed | Device: Eversense® CGM System | Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 273 | 2019-03-19 | 2024-02-01actual | — | 2025-06-12 |
| MNKD | Mannkind Corporation | $1.3B | Afrezza® INHALE-1 Study in PediatricsNCT04974528Change in HbA1c | Phase 3 | Completed | Biological: Afrezza, Rapid-acting Insulin Analog, Basal Insulin | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 319 | 2021-09-29 | 2024-10-03actual | — | 2025-05-06 |
| MNKD | Mannkind Corporation | $1.3B | Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 DiabetesNCT05243628results2024-10-18Change in HbA1c | Phase 4 | Completed | Biological: Afrezza (insulin human) Inhalation Powder, insulin degludec · Device: Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID) | Type 1 Diabetes | 33 | 2022-03-31 | 2022-10-17actual | — | 2025-04-08 |
| PODD | Insulet Corporation | $10.3B | Pivotal Omnipod Horizon™ Automated Glucose Control SystemNCT04196140results2024-05-14Incidence Rate of Severe Hypoglycemia (Events Per Person Months) | Not applicable | Completed | Device: Omnipod Horizon™ Automated Glucose Control System | Type 1 Diabetes Mellitus | 240 | 2019-12-30 | 2020-07-10actual | — | 2025-04-03 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)NCT05422053results2024-04-17Number of Severe Hypoglycemic Events | Not applicable | Completed | Device: t:slim X2 insulin pump with Control-IQ technology 1.5 | Type 1 Diabetes | 34 | 2022-06-29 | 2023-01-06actual | — | 2025-04-03 |
| BBNX | Beta Bionics, Inc. | $856M | The iLet Experience StudyNCT06891898observationalSevere Hypoglycemia/cognitive impairment | — | Recruiting | Device: iLet Dosing Decision Software | Type 1 Diabetes | 1,875 | 2024-05-01 | Jun 2027 | ≤ 314 d | 2025-03-24 |
| NVO | Novo Nordisk A/S | — | A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a WeekNCT03723772AUCI287,τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state | Phase 1 | Completed | Drug: Insulin icodec, IGlar U100 | Diabetes Mellitus, Type 1 | 66 | 2018-11-29 | 2020-06-26actual | — | 2025-03-11 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 DiabetesNCT05683392results2024-12-20Number of Severe Hypoglycemic Events | Not applicable | Completed | Device: t:slim X2 insulin pump with Control-IQ technology 2.0 | Type 1 Diabetes | 72 | 2023-02-01 | 2023-12-13actual | — | 2024-12-20 |
| 4503.T | Astellas Pharma Inc | $26.0B | Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes MellitusNCT02529449Daily profile of plasma glucose levels | Phase 2 | Completed | Drug: Placebo, ASP1941 | Type 1 Diabetes Mellitus | 43 | 2015-09-01 | 2016-03-19actual | — | 2024-11-12 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes MellitusNCT02897219Change from baseline in HbA1c | Phase 3 | Completed | Drug: ipragliflozin, Placebo · Other: Insulin Therapy | Type 1 Diabetes Mellitus | 175 | 2016-08-29 | 2017-07-22actual | — | 2024-11-12 |
| BDX | Becton, Dickinson and Company | $49.2B | Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen NeedlesNCT01231984results2014-06-27Glycemic Control as Measured by HbA1c (4 mm vs. 8 mm) | Not applicable | Completed | Device: 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 293 | Oct 2010 | May 2012actual | — | 2024-09-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 DiabetesNCT05262387results2024-09-03Pharmacodynamics (PD): Change in Plasma Glucose (PG) From the Start to the End of Exercise | Phase 1 | Completed | Drug: Lyumjev with 50% basal rate reduction, Humalog with 50% basal rate reduction, Humalog with 100% basal rate reduction, Lyumjev with 100% basal rate reduction | Diabetes Mellitus, Type 1 | 25 | 2022-02-14 | 2023-03-07actual | — | 2024-09-03 |
| SENS | Senseonics, Inc. | $459M | PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 DaysNCT03808376results2024-08-20Effectiveness Measure - Mean Absolute Relative Difference (MARD) for Paired CGM and Reference Glucose Measurements | Not applicable | Completed | Device: Continuous Glucose Monitoring System | Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 208 | 2018-12-27 | 2020-05-08actual | — | 2024-08-20 |
| MNKD | Mannkind Corporation | $1.3B | INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 DiabetesNCT05904743Change in glycated hemoglobin (HbA1c) | Phase 4 | Completed | Biological: Afrezza, insulin degludec, Rapid-acting Insulin Analog, Basal Insulin | Diabetes Mellitus, Type 1 | 141 | 2023-07-07 | 2024-03-26actual | — | 2024-08-09 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 DiabetesNCT05403502results2024-07-26Severe Hypoglycemia | Not applicable | Completed | Device: t:slim X2 insulin pump with Control-IQ technology 1.5 | Type 1 Diabetes | 183 | 2022-08-31 | 2023-08-02actual | — | 2024-07-26 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 DiabetesNCT04992312results2024-05-23Number of Participants With One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Completed | Drug: Glucagon Nasal Powder [Baqsimi] | Type 1 Diabetes | 7 | 2022-03-24 | 2023-11-05actual | — | 2024-05-23 |
| SNY | Sanofi | — | Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin GlargineNCT03874715results2023-07-21Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Timepoint (AUClast) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm) | Phase 3 | Completed | Drug: Insulin Aspart SAR341402, Insulin Aspart, Insulin glargine U100 | Type 1 Diabetes Mellitus | 210 | 2019-03-11 | 2020-07-08actual | — | 2024-04-17 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes With AID UseNCT05204134results2024-04-05Severe Hypoglycemic Events | Not applicable | Completed | Device: Automated Insulin Delivery Settings Initialization and Adaptation Algorithm | Type 1 Diabetes | 33 | 2022-03-24 | 2022-09-09actual | — | 2024-04-05 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3532226 in Participants With Type 1 Diabetes MellitusNCT05887999Pharmacodynamics (PD): Area under the concentration versus time curve from time 60 to 120 minutes (AUC60-120min) of plasma glucagon during the insulin-induced hypoglycemia | Phase 1 | Completed | Drug: LY3532226, Placebo | Diabetes Mellitus, Type 1 | 30 | 2023-06-12 | 2024-02-21actual | — | 2024-03-26 |
| BDX | Becton, Dickinson and Company | $49.2B | The Role of Proper Insulin Injection Technique in the Treatment of Diabetes MellitusNCT04120974results2024-02-22Change in Glycemic Control | Not applicable | Completed | Behavioral: Optimal insulin injection | Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Lipohypertrophy | 90 | 2019-10-01 | 2021-04-26actual | — | 2024-02-22 |
| PODD | Insulet Corporation | $10.3B | Omnipod Horizon™ Automated Glucose Control System Preschool CohortNCT04476472results2024-02-14Incidence Rate of Severe Hypoglycemia (Events Per Person Months) | Not applicable | Completed | Device: Omnipod Horizon™ Automated Glucose Control System | Type 1 Diabetes Mellitus | 80 | 2020-09-08 | 2022-01-17actual | — | 2024-02-14 |
| SENS | Senseonics, Inc. | $459M | PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and AlgorithmNCT03251079results2024-02-12Accuracy of CGM System Through 90 Days Post-Insertion (MARD for Paired CGM and Reference Glucose Measurements) | Not applicable | Completed | Device: Continuous glucose monitoring system | Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 36 | 2017-07-25 | 2018-02-01actual | — | 2024-02-12 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | Sigi Insulin Management System - A First-in-Human Study in Adults With Type 1 DiabetesNCT05973422Serious Adverse Events | Not applicable | Unknown status | Device: SIGI Insulin Management System | Type 1 Diabetes | 10 | 2024-05-31 | 2024-09-30 | — | 2024-01-11 |
| NVO | Novo Nordisk A/S | — | Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 DiabetesNCT00447382results2011-05-12Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies | Phase 3 | Completed | Drug: insulin detemir, insulin aspart, insulin detemir | Diabetes, Diabetes Mellitus, Type 1 | 330 | Mar 2007 | Jul 2008actual | — | 2024-01-02 |
| NVO | Novo Nordisk A/S | — | Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 DiabetesNCT00671008observationalGlycaemic control as measured by HbA1c | — | Completed | Drug: biphasic insulin aspart 30, insulin detemir | Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 400 | Dec 2007 | Sep 2008actual | — | 2024-01-02 |
| MGNX | MacroGenics | $261M | Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00920582results2023-12-20Proportion of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%. | Phase 3 | Terminatedsponsor's stated reason: Business decision | Biological: Teplizumab Herold Regimen, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen · Drug: Placebo | Type 1 Diabetes Mellitus | 254 | Sep 2009 | Apr 2012actual | — | 2023-12-20 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | Diabetes Pump With Predictive Low Glucose Suspend Pivotal TrialNCT03195140results2023-12-08Hypoglycemia < 70 mg/dL | Not applicable | Completed | Device: Predictive Low Glucose Suspend | Diabetes Mellitus, Type 1 | 103 | 2017-08-11 | 2018-02-06actual | — | 2023-12-08 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | Control-IQ Observational (CLIO) Post-Approval StudyNCT04503174results2023-12-08observationalIncidence Rates of Severe Hypoglycemia (SH) | — | Completed | Device: t:slim X2 pump with Control-IQ technology | Diabetes Mellitus, Type 1 | 3,157 | 2020-08-04 | 2023-06-02actual | — | 2023-12-08 |
| MGNX | MacroGenics | $261M | The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00385697results2023-12-05Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%. | Phase 2/3 | Completed | Biological: Teplizumab · Drug: Placebo | Type 1 Diabetes Mellitus | 554 | Oct 2006 | Jun 2010actual | — | 2023-12-05 |
| NVO | Novo Nordisk A/S | — | Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes MellitusNCT00655200observationalSafety profile of Insulin Detemir among Filipino patients | — | Completed | Drug: insulin detemir | Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 2,286 | Feb 2008 | Sep 2008actual | — | 2023-11-22 |
| PODD | Insulet Corporation | $10.3B | Prepivotal Omnipod Horizon™ Automated Glucose Control SystemNCT04176731results2023-11-13Proportion of Subjects With Severe Hypoglycemia | Not applicable | Completed | Device: Omnipod Horizon™ Automated Glucose Control System | Type 1 Diabetes Mellitus | 36 | 2019-12-15 | 2020-01-31actual | — | 2023-11-13 |
| PODD | Insulet Corporation | $10.3B | Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator StudyNCT04320069results2023-11-13Percentage of Time <70 mg/dL | Not applicable | Completed | Device: Omnipod Horizon™ Automated Glucose Control System | Type 1 Diabetes | 25 | 2020-06-09 | 2020-09-29actual | — | 2023-11-13 |
| NVO | Novo Nordisk A/S | — | The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting InsulinsNCT00313742The difference between plasma glucose concentrations immediately pre-exercise and the minimum plasma glucose concentrations (nadir) in the period 0-150 min following exercise | Phase 4 | Completed | Drug: insulin detemir, insulin glargine, insulin NPH | Diabetes, Diabetes Mellitus, Type 1 | 51 | Apr 2006 | Nov 2006actual | — | 2023-11-02 |
| NVO | Novo Nordisk A/S | — | Observational Study to Evaluate the Safety While Using Levemir®NCT00701155observationalIncidence of serious ADRs incl. major hypoglycemias | — | Completed | Drug: insulin detemir | Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 3,593 | Jul 2007 | Mar 2008actual | — | 2023-11-02 |
| NVO | Novo Nordisk A/S | — | Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney DiseaseNCT00849316observationalIncidence of major hypoglycaemic episodes | — | Withdrawnsponsor's stated reason: Due to company decision to focus resources on the finalisation of three ongoing studies in the region | Drug: insulin aspart | Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Chronic Kidney Disease | 0 | Feb 2009 | Nov 2009 | — | 2023-11-02 |
| NVO | Novo Nordisk A/S | — | A Survey to Evaluate Diabetes Management, Control, Complications and Psychosocial Aspects of Diabetic Patients in PhilippinesNCT00874159observationalMean age of onset of type 1 diabetes mellitus | — | Completed | Other: No treatment given | Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 770 | Apr 2009 | Oct 2009actual | — | 2023-11-02 |
| NVO | Novo Nordisk A/S | — | A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in KoreaNCT00918151observationalMean age of onset of type 1 and type 2 diabetes mellitus, respectively | — | Completed | Other: No treatment given | Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 1,932 | May 2009 | Sep 2009actual | — | 2023-11-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Type 1 Diabetes is matched — 9 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Diabetes Mellitus, Type 1
- Type 1 Diabetes Mellitus
- Type 1 Diabetes
- Diabetes Mellitus Type 1
- Type1 Diabetes Mellitus
- Diabetes Mellitus, Insulin-Dependent
- Type 1 Diabetes (T1D)
- Diabetes Type 1
- Diabetes, Type 1
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Type 1 Diabetes” (a text search, wider than this page)